Item 12: Adoption of the report of the Commission on its sixty-seventh session CND Chair (Ghana): Excellencies, distinguished representatives, ladies and gentlemen. Good afternoon. We shall now turn our attention to item 12, adoption of the report of the Commission on its 67th session. We will proceed with the adoption of the draft resolutions. Before doing …
Item 5b UNODC, Drugs, Laboratory and Scientific Services Branch (DLSSB): Thank you, Mr. Chair. distinguished delegates, ladies and gentlemen, as you’re well aware that new psychoactive substances are not under international control, but they produce the same harmful effects as the ones we have under control. In just over a decade, the number of these …
UNODC: Thank you Mr. Chair. Notable progress has been made. We have taken robust institutional steps. Programs have been consolidated to improve efficiency. New frameworks have been developed such as a new regional framework for the Arab states to guide the office in better supporting the member states. Program delivery reached $383.9 million, an increase …
Chair: Good Morning. The focus of our discussion pertains to Strategic Management budgetary and administrative motions in the context of our economy. Yesterday, in collaboration with the CCP CJ, we deliberated on the Consolidated budget for the biennium 2024-2025 for the United Nations Office on Drugs and Crime, referencing Containers document 5.2 (2013) and 15/2017, …
Chair: I am grateful for your cooperation earlier this year. We had previously discussed the Resolution, outlining the review process, and collectively decided to convene before he regular committee session. The high-level segment is scheduled for March 14th and 15th, dedicated to assessing the implementation of international drug policy commitments. During this segment, we aim …
Chair: Good Morning. Yesterday we had a fruitful discussion on the issues of the consequences and risk associated with non medical use of drugs. Today we will be discussing the low availability of nationally controlled substances for medical and scientific purposes, including for the relief of pain and palliative care. Before we start a discussion, …